Target- |
MechanismMagnetic resonance imaging enhancers |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date03 Oct 2005 |
A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.
100 Clinical Results associated with TMC Pharma Services Ltd.
0 Patents (Medical) associated with TMC Pharma Services Ltd.
100 Deals associated with TMC Pharma Services Ltd.
100 Translational Medicine associated with TMC Pharma Services Ltd.